fashion -WSS

fashion

author：hotspot 2025-09-27 12:57:31 - browse：11126

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Biden administration plans revamp of organ transplant system

Wikipedia

WSS

A public health expert passes on football's full body collisions for youths

How Medicaid coverage policies for immigrants impact new moms

How dance can help nurses traumatized by Covid

Medicare has a new plan to address drug shortages

Custom gene therapy hints at new path for rare disease treatments

How to fix the rural physician shortage in the U.S.

hotspot

fashion

knowledge

Sports medicine is finally prioritizing gender equality

The thinking behind the controversial eating disorder chatbot Tessa

Trump demands the U.S. pay no more for drugs than other countries … again

FDA approves RSV monoclonal antibody for infants, toddlers

Activists slam private health insurers over coverage restrictions

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

In Memoriam: Notable people who died in 2023

Millions may soon lose Medicaid when they don't have to

Psychedelics group wrestles with new pharma identity

Sanders adds drug shortage policies to pandemic preparedness bill

leisure time

Altering the blood type of lungs raises potential for universal organs for transplants

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Reanimated hearts work just as well for transplants, study finds

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Millions may soon lose Medicaid when they don't have to

focus

Wikipedia

focus

knowledge